38 results about "Clostridium perfringens infection" patented technology

The invention discloses recombinant alpha protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant alpha protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.353 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The recombinant alpha protein enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the recombinant alpha protein. The recombinant alpha protein is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention discloses recombinant epsilon protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant epsilon protein is (a) protein formed by amino acid sequences shown in SEQ ID No.2 or (b) protein formed by amino acid sequences from the 51 site to the 370 site in SEQ ID No.2 or fusion protein obtained by fusing protein tags on carboxyl terminals or / and amino terminals of the (a) protein or the (b) protein. After animals are immune to the recombinant epsilon protein, the animals can generate the high serum antibody level and can resist attack of clostridium perfringens. The recombinant epsilon protein is good in dissolvability and easy to purify and can be taken as a diagnostic antigen or prepared into a monoclonal antibody or used for further studying the protein function and the conformation relationship.

The invention discloses a recombinant lactobacillus for simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin, a construction method of the recombinant lactobacillus and an application. The recombinant lactobacillus takes the clostridium perfringens alpha, beta 1, beta 2 and epsilon exotoxin reconstructed from gene levels in a toxicity removal manner as immunogen, the reconstructed exotoxin completely loses pathogenicity and still retains immunogenicity, and the lactobacillus serves as a safe living bacterium carrier for transmitting and expressing immunizing antigens, so that the recombinant lactobacillus capable of simultaneously expressing clostridium perfringens alpha, beta 2, epsilon and beta 1 exotoxin is acquired, and a gene engineering lactobacillus multi-valence subunit toxin oral immune preparation capable of effectively preventing infection of five serotype clostridium perfringens is prevented. The recombinant lactobacillus provides effective technical means for preventing infection of the clostridium perfringens.

The invention discloses a ssc-miR-122-5p related to piglet type C Clostridium perfringens infectious diarrhea, the nucleotide sequence of the ssc-miR-122-5p is shown in SEQ ID NO.1 . The present invention also discloses specific primers for detecting the expression level of ssc-miR-122-5p, the sequence of which is shown in SEQ ID NO.2. The invention discloses a method for improving piglet resistance to type C Clostridium perfringens infection by interfering with ssc-miR-122-5p. The present invention found for the first time that ssc-miR-122-5p was significantly highly expressed in the ileum tissue of piglets with Clostridium perfringens type C infectious diarrhea, and then IPEC-J2 cells were used as the research object to overexpress and interfere with ssc-miR ‑122‑5p studied its effect on CPB2 toxin-induced IPEC‑J2 cell damage, in order to elucidate the mechanism of ssc‑miR‑122‑5p involved in the regulation of diarrhea caused by Clostridium perfringens type C infection, which is a bacterium in piglets Molecular breeding of sexual diarrhea provides a powerful scientific reference.

The invention relates to a type C and D type Clostridium perfringens antitoxin serum and a preparation method thereof; the C type Clostridium perfringens strain and the D type Clostridium perfringens strain are respectively inoculated on a blood plate Resuscitate on the medium, and then use the nutrient broth to enrich the bacteria for anaerobic culture to obtain the C-type Clostridium perfringens liquid and the D-type Clostridium perfringens liquid respectively, and then use the toxin-producing medium to cultivate and inactivate. It is isolated from serum after basic immunization and booster immunization. The antitoxin serum of C and D type Clostridium perfringens prepared by the present invention has high titer, strong specificity and no side effects; it can be used for the immunity of C and D types of Clostridium perfringens in animals, and can be used in research Pre-control plays an important role in the epidemic of sheep sudden attack and enterotoxemia caused by type C, D or C and D two types of Clostridium perfringens infection.

The present invention relates to generation and high level expression of recombinant non-toxic of epsilon toxin of Clostridium perfringens as a recombinant vaccine against Clostridium perfringens infection and a process for producing the vaccine involving amplifying, cloning, transforming, incubating and purifying the recombinant non-toxic epsilon toxin protein. Thus in this invention, substitution mutation Y71G was executed in recombinant Etx and the recombinant EtxY71G protein was over-expressed in soluble form. Expressed protein was purified near homogeneity by DEAE sepharose anion exchange chromatography with high yield. Potential of rEtxY71G as a vaccine candidate was evaluated and found to be highly specific and immunogenic. The present invention is the first report for high level expression of non toxic rEtxY71G mutant protein of Clostridium perfringens. Upto 100 mg / L of highly immunogenic and homogeneous recombinant EtxY71G protein of 31 kDa was produced. Further, the immunization with rEtxY71G gave very high titer and conferred protection against epsilon toxin intoxication.

The invention discloses a fusion protein vaccine for inhibiting clostridium perfringens infection. The vaccine contains protein shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.937 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The vaccine enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the vaccine. The immune protective rates of the vaccine within seven days when the vaccine resists the attack of clostridium perfringens type A, clostridium perfringens type B, clostridium perfringens type C and clostridium perfringens type D are 100%, 100%, 90% and 100% correspondingly, and the highest antibody valence is up to 1:128,000.

The invention discloses a preparation method of fusion protein for inhibiting clostridium perfringens infection. The method comprises the step that encoding genes of protein are expressed in organisms to obtain the fusion protein, wherein the organisms are microorganisms or plants or non-human animals; the protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.937 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or / and amino terminals of the protein shown in (a) or (b). The fusion protein prepared through the method is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention discloses a compound composition of citral and carvacrol and its application. The combination of citral and carvacrol can inhibit the growth of Clostridium spp, can effectively control the number of Clostridium spp. in the intestinal tract of poultry, and can not only reduce the mortality of broiler chickens with necrotizing enteritis, the score of necrotizing enteritis lesions and the production of caecal contents. The number of Clostridium perfringens can also promote the growth performance of broilers with necrotizing enteritis, increase the average daily feed intake and final body weight, and promote the growth of broilers with necrotizing enteritis. It can be used to prevent necrotizing enteritis caused by Clostridium perfringens infection Enteritis and has a good application prospect.